ACROFAST Findings: Personalized Care for Acromegaly Wins on Both Health and Budget

A precision-medicine protocol for treating acromegaly can slash healthcare costs by 22% while more than doubling a patient’s chances of reaching hormonal remission, according to an economic analysis of the ACROFAST clinical trial. “ Cost-effectiveness of personalized medical treatment in acromegaly: a post hoc analysis of the ACROFAST study ,” a Spanish study recently published in the Journal of the Endocrine Society , signals a major shift away from the traditional “one-size-fits-all” approach to this rare and debilitating hormonal disorder.

By utilizing a €121 ($135.52) biomarker test to bypass months of ineffective trial-and-error therapy, researchers found they could save an average of €15,263 ($17,094.56) per controlled patient annually — a finding with massive implications for cash-strapped public health systems worldwide. Acromegaly, typically caused by a benign pituitary tumor, triggers an overproduction of growth hormone that leads to physical disfigurement and severe systemic complications, including cardiovascular disease and diabetes, if left unchecked.

For decades, the clinical standard has been a rigid step-care model: Start nearly all patients on first-generation somatostatin receptor ligands (fgSRLs).